|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1-3
|
|
pubmed:dateCreated |
2005-1-31
|
|
pubmed:abstractText |
Thiazolidinediones, a new class of antidiabetic drugs that increase insulin sensitivity, have been shown to be ligands for peroxisome proliferator-activated receptor gamma (PPARgamma). Recent studies demonstrating that PPARgamma occurs in macrophages have focused attention on its role in macrophage functions. In this study, we investigated the effect of thiazolidinediones on monocyte proliferation and migration in vitro and the mechanisms involved. In addition, we examined the therapeutic potentials of thiazolidinediones for injured atherosclerotic lesions. Troglitazone and pioglitazone, the two thiazolidinediones, as well as 15-deoxy-delta12,14-prostaglandin J2 inhibited in a dose-dependent manner the serum-induced proliferation of THP-1 (human monocytic leukemia cells) and of U937 (human monoblastic leukemia cells), which permanently express PPARgamma. These ligands for PPARgamma also significantly inhibited migration of THP-1 induced by monocyte chemoattractant protein-1 (MCP-1). Troglitazone and 15-deoxy-delta12,14-prostaglandin J2 significantly suppressed the mRNA expression of the MCP family-specific receptor CCR2 (chemokine CCR2 receptor) in THP-1 at the transcriptional level. Furthermore, troglitazone significantly inhibited MCP-1 binding to THP-1. Oral administration of troglitazone to Watanabe heritable hyperlipidemic (WHHL) rabbits after balloon injury suppressed acute recruitment of monocytes/macrophages and accelerated re-endothelialization. These results suggest that thiazolidinediones have therapeutic potential for the treatment of diabetic vascular complications.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/15-deoxy-delta(12,14)-prostaglandin...,
http://linkedlifedata.com/resource/pubmed/chemical/CCR2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CCL2,
http://linkedlifedata.com/resource/pubmed/chemical/Chromans,
http://linkedlifedata.com/resource/pubmed/chemical/PPAR gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin D2,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Chemokine,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones,
http://linkedlifedata.com/resource/pubmed/chemical/Tretinoin,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/alitretinoin,
http://linkedlifedata.com/resource/pubmed/chemical/pioglitazone,
http://linkedlifedata.com/resource/pubmed/chemical/troglitazone
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0014-2999
|
|
pubmed:author |
pubmed-author:AraiHiroshiH,
pubmed-author:ChunTae-HwaTH,
pubmed-author:DoiKentaroK,
pubmed-author:FukunagaYasutomoY,
pubmed-author:InoueMayumiM,
pubmed-author:ItohHiroshiH,
pubmed-author:MasatsuguKenK,
pubmed-author:NakaoKazuwaK,
pubmed-author:SaitoTakatoshiT,
pubmed-author:SakaguchiSatsukiS,
pubmed-author:SawadaNaokiN,
pubmed-author:TanakaTokujiT,
pubmed-author:YamashitaJunJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
31
|
|
pubmed:volume |
508
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
255-65
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15680279-Angioplasty, Balloon,
pubmed-meshheading:15680279-Animals,
pubmed-meshheading:15680279-Aorta,
pubmed-meshheading:15680279-Arteriosclerosis,
pubmed-meshheading:15680279-Binding, Competitive,
pubmed-meshheading:15680279-Cell Line,
pubmed-meshheading:15680279-Cell Line, Tumor,
pubmed-meshheading:15680279-Cell Movement,
pubmed-meshheading:15680279-Cell Proliferation,
pubmed-meshheading:15680279-Chemokine CCL2,
pubmed-meshheading:15680279-Chromans,
pubmed-meshheading:15680279-Dose-Response Relationship, Drug,
pubmed-meshheading:15680279-Endothelium, Vascular,
pubmed-meshheading:15680279-Gene Expression Regulation,
pubmed-meshheading:15680279-Humans,
pubmed-meshheading:15680279-Macrophages,
pubmed-meshheading:15680279-Male,
pubmed-meshheading:15680279-Monocytes,
pubmed-meshheading:15680279-PPAR gamma,
pubmed-meshheading:15680279-Prostaglandin D2,
pubmed-meshheading:15680279-RNA, Messenger,
pubmed-meshheading:15680279-Rabbits,
pubmed-meshheading:15680279-Receptors, CCR2,
pubmed-meshheading:15680279-Receptors, Chemokine,
pubmed-meshheading:15680279-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:15680279-Thiazolidinediones,
pubmed-meshheading:15680279-Time Factors,
pubmed-meshheading:15680279-Tretinoin,
pubmed-meshheading:15680279-Vascular Endothelial Growth Factor A,
pubmed-meshheading:15680279-Wound Healing
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration.
|
|
pubmed:affiliation |
Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
